FEATURED EDITORIAL
Praise to the RNA innovators, and our innovative service providers. You’ve brought us a long way. Still, that progress hasn’t necessarily made it easier to strategize the outsourcing of specific RNA-based projects. We’ve expanded development programs therapeutically and dialed up nuanced production requirements. So the current question is what will the RNA outsourcing ecosystem look like a few years from now? Here’s some expert analysis.
- DEA Reveals Hidden Costs Of Analytical Validation Guidelines
- Qualification And Validation Of Depyrogenation Tunnels And Autoclaves
- Your CDMO Can Make It, But Can Your Market Afford It?
- FDA Modernizes Container Closure Guidance: What Is Changing And Why It Matters
- CDMO Selection Beyond Capabilities And Price
- August 2026 — CDMO Opportunities And Threats Report
- Dr. Heidi Overton And The FDA: An Outsourcing Perspective
GUEST COLUMNISTS
-
Qualification And Validation Of Depyrogenation Tunnels And Autoclaves
Systemic vulnerabilities exist in thermal uniformity assurance, steam penetration verification, regulatory fragmentation, and tech harmonization.
-
FDA Modernizes Container Closure Guidance: What Is Changing And Why It Matters
The proposed revision reflects changes in packaging technology, drug delivery systems, quality risk management, and more that have occurred since 1999's guidance.
-
CDMO Selection Beyond Capabilities And Price
Some of the most useful information relevant to CDMO selection is also the hardest to obtain. Here are suggestions for uncovering data that tells the whole capability story.
-
August 2026 — CDMO Opportunities And Threats Report
Each month, Outsourced Pharma works in conjunction with PharmSource, part of GlobalData, to present its “Contract Manufacturing: Opportunities and Threats (CMOT) Report” to our readers. The report identifies CDMOs that might be impacted by key events affecting their clients, including company acquisitions, product acquisitions and licenses, product approvals, late clinical product terminations, and FDA rejections.
-
Building Sustainable Biopharma Supply Chains Starts With Procurement
Nearly all the industry's emissions happen upstream from core manufacturing functions. This puts sustainability almost entirely on the shoulders of purchasing.
-
Why You Should Measure Comparability Debt Before Ever Starting A Study
When analytical capability and process understanding fail to keep pace with a drug candidate, the technical uncertainty creates debt that's difficult to pay down.
-
What FDA Inspectors Want From Your OOS File
Read enough FDA warning letters and a pattern emerges: Investigators rarely cite a retest that was performed badly. They cite a retest that nobody justified in writing. Let's take a closer look.
-
You Can't CAPA What You Can't Classify
An LLM or agentic error can occur with no component broken in any way the QMS recognizes. Classifying it takes two fields: the error type and the error origination point.
PHARMA OUTSOURCING WHITE PAPERS
-
Why An Integrated Approach Ensures Smooth Entry Into The European Market
Simplify your EU launch and boost returns. Learn how to manage regulatory hurdles, access a huge patient population, and gain end-to-end commercial support.
-
Sustainability In Small Molecule API Manufacturing
Redesigning chemical processes with green chemistry principles can cut emissions, reduce waste, and improve efficiency. See how smarter synthesis and digital tools enable sustainable API manufacturing.
-
Advancing ADCs With Expertise In Payloads And Linkers
Discover how integrated containment, high-potency expertise, advanced chromatography, and proven linker–payload process optimization can accelerate your ADC program from early development to reliable commercial supply.
-
Selecting A CDMO For Custom Activated PEGs
Custom-activated PEGs require thoughtful planning and precise analytical control. Discover key considerations for selecting a partner capable of supporting scalable, compliant PEGylation.
-
A Shift Towards Biofluorescent Particle Counters In Manufacturing
Sterility in injectable drug manufacturing is vital for patient safety and efficiency. Discover how biofluorescent particle counters revolutionize contamination control, regulatory compliance, and operational excellence in modern pharma.
-
The Relevance Of Polymorph Screening In The Pharmaceutical Industry
Polymorph screening identifies different solid forms of active pharmaceutical ingredients, optimizing drug stability, solubility, and manufacturability. This process ensures quality, regulatory compliance, and intellectual property protection in pharmaceutical development.
PHARMA OUTSOURCING APP NOTES & CASE STUDIES
REPORTING
PRODUCTS & SERVICES
ON-DEMAND WEBINARS
- Design Verification Done Right: Smarter Strategies For Prefillable Syringes
- IND In As Little As 6 Months: Now Beyond mAbs - Accelerating Bispecifics, Fc-Fusions And High-Concentration Biologics To The Clinic
- Scaling Cell And Gene Therapy Manufacturing
- Mastering The Path: Developing Processes For Successful Clinical-Grade mRNA Manufacturing
- De-Risking The Path To GMP Manufacturing At Another Organization